Intestinal fatty acid binding protein as biomarker of enterocyte injury in patients with renal failure
- 作者: Pyatchenkov M.O.1, Sherbakov E.V.1, Trandina A.E.1, Belskykh A.N.1
-
隶属关系:
- Military Medical Academy
- 期: 卷 15, 编号 3 (2023)
- 页面: 37-41
- 栏目: Original Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/624729
- DOI: https://doi.org/10.18565/nephrology.2023.3.30-36
- ID: 624729
如何引用文章
详细
Aim: to evaluate serum intestinal fraction of the fatty acid binding protein (I-FABP) in subjects at different stages of chronic kidney disease (CKD), including those receiving hemodialysis treatment.
Material and methods. The cross-sectional study included 3 groups of patients: 1) 20 relatively healthy individuals with GFR>60 ml/min/1.73 m2; 2) 30 patients with CKD C3a-5 (GFR<60 ml/min/1.73 m2); 3) 38 patients with end-stage renal disease (ESRD) receiving hemodialysis treatment. All participants had no clinical manifestations of intestinal pathology. The concentration of I-FABP in blood serum was assessed by ELISA using commercially available kit.
Results. I-FABP levels significantly increased in parallel with an advance of renal insufficiency and reached maximum values in patients with ESRD: 1719,5 (1279,8–1979,6), 3533,2 (2449,5–4234,1), 6340,7 (5436–6732,3) pg/ml respectively. In subjects at the predialysis stages of CKD, a strong inverse correlation of I-FABP with GFR was found (R=0,946, p<0.001).
Conclusion. A decrease in GFR leads to a significant increase of serum I-FABP levels in patients with impaired renal function. This should be taken into account when using I-FABP as a biomarker of enterocytes injury in patients with renal failure.
全文:
作者简介
Mikhail Pyatchenkov
Military Medical Academy
Email: pyatchenkovMD@yandex.ru
ORCID iD: 0000-0002-5893-3191
SPIN 代码: 5572-8891
candidate of medical Sciences, senior lecturer of Department of nephrology and blood purification
俄罗斯联邦, 6, str. Akademika Lebedeva, 194044 Saint PetersburgEvgeniy Sherbakov
Military Medical Academy
Email: evgenvmeda@mail.ru
ORCID iD: 0000-0002-3045-1721
SPIN 代码: 6337-6039
nephrologist in the Military Medical Academy
俄罗斯联邦, 6, str. Akademika Lebedeva, 194044 Saint PetersburgAleksandra Trandina
Military Medical Academy
Email: sasha-trandina@rambler.ru
ORCID iD: 0000-0003-1875-1059
SPIN 代码: 6089-3495
doctor of clinical laboratory diagnostics Research department (Biomedical Research) of the RC
俄罗斯联邦, 6, str. Akademika Lebedeva, 194044 Saint PetersburgAndrei Belskykh
Military Medical Academy
编辑信件的主要联系方式.
Email: d0c62@mail.ru
ORCID iD: 0000-0002-0421-3797
Scopus 作者 ID: 273050
doctor of medical Sciences, Professor, Corresponding Member, Russian Academy of Sciences, Head of Department of nephrology and blood purification
俄罗斯联邦, 6, str. Akademika Lebedeva, 194044 Saint Petersburg参考
- Thenet S., Carrière V. Special Issue on the "Regulation and Physiopathology of the Gut Barrier". Int. J. Mol. Sci. 2022;23(18):10638. doi: 10.3390/ijms231810638.
- Okumura R., Takeda K. Roles of intestinal epithelial cells in the maintenance of gut homeostasis. Exp. Mol. Med. 2017;49(5):e338. doi: 10.1038/emm.2017.20.
- Higashiyama M., Miura S., Hokari R. Modulation by luminal factors on the functions and migration of intestinal innate immunity. Front. Immunol. 2023;14:1113467. doi: 10.3389/fimmu.2023.1113467.
- Di Tommaso N., Santopaolo F., Gasbarrini A., at al. The Gut-Vascular Barrier as a New Protagonist in Intestinal and Extraintestinal Diseases. Int. J. Mol. Sci. 2023;24(2):1470. doi: 10.3390/ijms24021470.
- Ткаченко Е.И., Гриневич В.Б., Губонина И.В. и др. Болезни как следствие нарушений симбиотических взаимоотношений организма хозяина с микробиотой и патогенами. Вестн. Российской Военно-медицинской академии. 2021;23(2):243–52. doi: 10.17816/brmma58117. [Tkachenko E., Grinevich V., Gubonina I., et al. Disease as a result of violations of the symbiotic relationship between the host and the microbiota with pathogens. Bull. Rus. Military Med. Acad. 2021;23(2):243–52 (In Russ.)].
- Grootjans J., Thuijls G., Verdam F., at al. Non-invasive assessment of barrier integrity and function of the human gut. World J. Gastrointest. Surg. 2010;2(3):61–9. doi: 10.4240/wjgs.v2.i3.61.
- Treskes N., Persoon A., van Zanten A. Diagnostic accuracy of novel serological biomarkers to detect acute mesenteric ischemia: a systematic review and meta-analysis. Intern. Emerg. Med. 2017;12(6):821–36. doi: 10.1007/s11739-017-1668-y.
- Li S., Chen Y., Chen T., at al. Mesenteric ischemia in patients with end-stage renal disease: a nationwide longitudinal study. Am. J. Nephrol. 2012;35(6):491–7. doi: 10.1159/000338451.
- Ori Y., Chagnac A., Schwartz A., et al. Non-occlusive mesenteric ischemia in chronically dialyzed patients: a disease with multiple risk factors. Nephron. Clin. Pract. 2005;101(2):c87–93. doi: 10.1159/000086346.
- Пятченков М.О., Власов А.А., Щербаков Е.В. и др. Особенности оценки проницаемости кишечного барьера при хронической болезни почек. Экспериментальная и клиническая гастроэнтерология. 2022;11:46–59. doi: 10.31146/1682-8658-ecg-207-11-46-59. [Pyatchenkov M., Vlasov A., Sherbakov E., et al. Features of assessing the intestinal barrier permeability in chronic kidney disease. Exp. Clin. Gastroenterol. 2022;(11):46–59 (In Russ.)].
- Pelsers M., Namiot Z., Kisielewski W., et al. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin. Biochem. 2003;36(7):529–35. doi: 10.1016/s0009-9120(03)00096-1.
- Sun D., Cen Y., Li S., at al. Accuracy of the serum intestinal fatty-acid-binding protein for diagnosis of acute intestinal ischemia: a meta-analysis. Sci. Rep. 2016;6:34371. doi: 10.1038/srep34371.
- Seethaler B., Basrai M., Neyrinck A., et al. Biomarkers for assessment of intestinal permeability in clinical practice. Am. J. Physiol. Gastrointest. Liver Physiol. 2021;321(1):G11–7. doi: 10.1152/ajpgi.00113.2021.
- Matsumoto S., Sekine K., Funaoka H., et al. Diagnostic performance of plasma biomarkers in patients with acute intestinal ischaemia. Br. J. Surg. 2014;101(3):232–38. doi: 10.1002/bjs.9331.
- Habes Q., van Ede L., Gerretsen J., at al. Norepinephrine Contributes to Enterocyte Damage in Septic Shock Patients: A Prospective Cohort Study. Shock. 2018;49(2):137–43. doi: 10.1097/SHK.0000000000000955.
- Timmermans K., Sir Ö., Kox M., et al. Circulating iFABP Levels as a marker of intestinal damage in trauma patients. Shock. 2015;43(2):117–20. doi: 10.1097/SHK.0000000000000284.
- Piton G., Belin N., Barrot L., et al. Enterocyte Damage: A Piece in the Puzzle of Post-Cardiac Arrest Syndrome. Shock. 2015;44(5):438–44. doi: 10.1097/SHK.0000000000000440.
- Sekino M., Okada K., Funaoka H., et al. Association between Enterocyte Injury and Mortality in Patients on Hemodialysis Who Underwent Cardiac Surgery: An Exploratory Study. J. Surg. Res. 2020;255:420–27. doi: 10.1016/j.jss.2020.05.091.
- Kitai T., Kim Y., Kiefer K., et al. Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure. Clin. Biochem. 2017;50(9):491–95. doi: 10.1016/j.clinbiochem.2017.02.014.
- Okada K., Sekino M., Funaoka H., et al. Intestinal fatty acid-binding protein levels in patients with chronic renal failure. J. Surg. Res. 2018;230:94–100. doi: 10.1016/j.jss.2018.04.057.
- Tsai I., Wu C., Hung W., et al. FABP1 and FABP2 as markers of diabetic nephropathy. Int. J. Med. Sci. 2020;17(15):2338–45. doi: 10.7150/ijms.49078.
- Yu T., Hsuan C., Wu C., et al. Association of plasma fatty acid-binding protein 3 with estimated glomerular filtration rate in patients with type 2 diabetes mellitus. Int. J. Med. Sci. 2022;19(1):82–8. doi: 10.7150/ijms.66876.